Skip to main content
Clinical Trials/NCT05302167
NCT05302167
Completed
N/A

Feasibility Study of an Adapted App-based Anxiety Intervention ('Molehill Mountain') for Autistic People.

King's College London2 sites in 1 country100 target enrollmentSeptember 6, 2022
ConditionsAnxietyAutism

Overview

Phase
N/A
Intervention
Not specified
Conditions
Anxiety
Sponsor
King's College London
Enrollment
100
Locations
2
Primary Endpoint
App acceptability/ feasibility survey
Status
Completed
Last Updated
last year

Overview

Brief Summary

Up to half of autistic people experience anxiety symptoms, which can have a significant impact on everyday wellbeing. However, there are currently very few effective, evidence-based interventions to support autistic people in managing anxiety; and many autistic people face barriers in accessing inperson health and social care services. Therefore, developing new interventions (and/ or adapting existing ones) that improve anxiety, in a way that meets the needs of autistic people, represents the autism community's number one priority for research and clinical practice.

Addressing this priority, the investigators will test the acceptability and feasibility of a new, app-based therapeutic approach for anxiety ('Molehill Mountain') that has been developed with, and adapted for, autistic people aged 12-years and over using adapted Cognitive Behavioural therapy principles. This means that information will be collected from autistic people accessing clinical services on whether they would choose to use the anxiety app, whether the app is simple to administer and use, how it is used, how it can be improved, and whether it is effective in reducing anxiety symptoms and/ or enhancing other outcomes, such as everyday wellbeing and functioning.

The evidence from this project will inform the future optimisation and implementation of Molehill Mountain in a randomised-controlled trial, with the ultimate aim of transforming long-term healthcare delivery for autistic people.

Registry
clinicaltrials.gov
Start Date
September 6, 2022
End Date
October 24, 2024
Last Updated
last year
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Age ≥ 16-years.
  • Autism diagnosis.
  • Current mild-to-severe anxiety symptom severity, as assessed at screening (and currently in touch with mental health services e.g., referred, on the waitlist).
  • Able and willing to provide verbal and written informed consent to take part in the study.
  • Access to Molehill Mountain app via SmartPhone or other Smart device.

Exclusion Criteria

  • Difficulties with reading/ writing to the extent that the app is inaccessible.
  • High risk of self-harm that make participation in the study inappropriate for the individual's current level of clinical need (as assessed by clinical team).
  • Attended ≥ 6 sessions of individual or group therapy (e.g., cognitive behavioural therapy) in the past 6-months, which would make it impossible to parse out the effects of the app from existing therapy.
  • If using psychotropic medication, this medication/ dose must have been stable for a minimum of 8-weeks on entry to the study.

Outcomes

Primary Outcomes

App acceptability/ feasibility survey

Time Frame: Week 13 (+/-2)

A survey developed by the investigator team to assess the acceptability and feasibility of Molehill Mountain app use by autistic adolescents/ adults in a clinically derived sample. Key indices incorporated in post-study app use experience surveys include: 1) the preparedness of participants to be randomised in a future trial; 2) ease of app administration and use; 3) preferred app features, content, and structure; 4) non-preferred app features, content, and structure; 5) experiences of app technical functionality; and 6) subjective reflections on the impact of app use on anxiety and everyday wellbeing/ functioning.

Change in 7-item Generalised Anxiety Disorder Scale (GAD-7)

Time Frame: Week 0 (+/-2); Week 13 (+/-2); Week 24 (+/- 4); Week 32 (+/-4); Week 41 (+/-4)

Minimum score = 0; Maximum score = 21; Higher scores indicate more severe anxiety.

Secondary Outcomes

  • Change in Medication/ service use(Week 0 (+/-2); Week 13 (+/-2); Week 24 (+/- 4); Week 32 (+/-4); Week 41 (+/-4))
  • Change in Goal Attainment Scaling(Week 0 (+/-2); Week 13 (+/-2); Week 24 (+/- 4); Week 32 (+/-4); Week 41 (+/-4))

Study Sites (2)

Loading locations...

Similar Trials